[go: up one dir, main page]

AR065911A1 - Beta - klotho - Google Patents

Beta - klotho

Info

Publication number
AR065911A1
AR065911A1 ARP080101364A ARP080101364A AR065911A1 AR 065911 A1 AR065911 A1 AR 065911A1 AR P080101364 A ARP080101364 A AR P080101364A AR P080101364 A ARP080101364 A AR P080101364A AR 065911 A1 AR065911 A1 AR 065911A1
Authority
AR
Argentina
Prior art keywords
klbeta
fgfr
antibody
sample
disorder
Prior art date
Application number
ARP080101364A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40229367&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065911(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR065911A1 publication Critical patent/AR065911A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5032—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on intercellular interactions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)

Abstract

Reivindicacion 1: Uso de una cantidad efectiva de un modulador de KLbeta para la manufactura de un medicamento para modular un trastorno asociado a la expresion o actividad de KLbeta a un individuo que necesite tal tratamiento. Reivindicacion 2:Uso de una cantidad efectiva de un antagonista de KLbeta para la manufactura de un medicamento para tratar un trastorno asociado a la expresion o actividad de KLbeta a un individuo que necesite tal tratamiento. Reivindicacion 3: El uso de lareivindicacion 2, donde el trastorno es un tumor, un cáncer o un trastorno de proliferacion celular. Reivindicacion 4: El uso de la reivindicacion 3, donde el tumor, cáncer o trastorno de proliferacion celular es carcinoma hepatocelular, cáncerpancreático, pulmonar de células no pequenas, de mama o colorrectal. Reivindicacion 6: El uso de la reivindicacion 5, donde el trastorno hepático es cirrosis. Reivindicacion 7: El uso de la reivindicacion 2, donde el trastorno es hipoglucemia,colestasis o disfuncion del metabolismo del ácido bílico, Reivindicacion 11: El uso de la reivindicacion 10, donde el segundo compuesto es un anticuerpo, un agente quimioterapéutico, citotoxico, antiangiogénico o inmunosupresor, un profármaco, unacitocina, un antagonista de citocinas, radioterapia citotoxica, un corticoesteroide, un antiemético, una vacuna contra el cáncer, un analgésico o un agente inhibidor del crecimiento. Reivindicacion 12: El uso de la reivindicacion 11, donde elsegundo compuesto es tamoxifeno, letrozol, exemestano, anastrozol, irinotecán, cetuximab, fulvestrant, vinorelbina, erlotinib, bevacizumab, vincristina, imatinib, sorafenib, lapatinib o trastuzumab. Reivindicacion 15: El uso de cualquiera de lasreivindicaciones 2-14, donde el antagonista de Klbeta es un anticuerpo. Reivindicacion 16: El uso de la reivindicacion 15, donde el anticuerpo es un anticuerpo monoclonal. Reivindicacion 17: El anticuerpo de la reivindicacion 15, donde elanticuerpo se selecciona del grupo formado por un anticuerpo quimérico, un anticuerpo humanizado, un anticuerpo con maduracion de afinidad, un anticuerpo humano y un anticuerpo biespecífico. Reivindicacion 25: El uso de la reivindicacion 24, dondeel trastorno es la obesidad o una afeccion relacionada con la obesidad. Reivindicacion 27: El uso de la reivindicacion 25, donde el trastorno es hiperglucemia. Reivindicacion 34: Un método para identificar una sustancia inhibidora candidata queinhiba la union de Klbeta a FGFR que consiste en: (a) poner en contacto una sustancia candidata con una primera muestra que contenga FGFR, FGF y KLbeta, y (b) comparar la cantidad de actividad biologica del FGFR en la muestra con la exhibida en unamuestra de referencia que comprenda cantidades similares de KLbeta, FGF y FGFR a las de la primera muestra pero no haya estado en contacto con dicha sustancia candidata, teniendo en cuenta que un descenso de la cantidad de actividad biologica delFGFR en la primera muestra en comparacion con la exhibida en la muestra de referencia indicaría que la sustancia candidata es capaz de inhibir la union de Klbeta a FGFR. Reivindicacion 35: Un método para determinar si una sustancia candidatapromueve la actividad biologica de la KLbeta que consiste en: (a) poner en contacto una sustancia candidata con una primera muestra que contenga FGFR y KLbeta, y (b) comparar la cantidad de actividad biologica del FGFR en la muestra con la exhibidaen una muestra de referencia que comprenda cantidades similares de KLbeta y FGFR a las de la primera muestra pero no haya estado en contacto con dicha sustancia candidata, teniendo en cuenta que un aumento de la cantidad de actividad biologica delFGFR en la primera muestra en comparacion con la exhibida en la muestra de referencia indicaría que la sustancia candidata es capaz de promover la union de Klbeta a FGFR.
ARP080101364A 2007-04-02 2008-04-01 Beta - klotho AR065911A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90969907P 2007-04-02 2007-04-02
US91618707P 2007-05-04 2007-05-04

Publications (1)

Publication Number Publication Date
AR065911A1 true AR065911A1 (es) 2009-07-08

Family

ID=40229367

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101364A AR065911A1 (es) 2007-04-02 2008-04-01 Beta - klotho

Country Status (21)

Country Link
US (7) US20100158914A1 (es)
EP (3) EP3372237A1 (es)
AR (1) AR065911A1 (es)
AU (1) AU2008275559B2 (es)
CA (1) CA2682096A1 (es)
CL (2) CL2008000947A1 (es)
DK (1) DK2550972T3 (es)
ES (2) ES2665996T3 (es)
HR (1) HRP20180667T1 (es)
HU (1) HUE038279T2 (es)
LT (1) LT2550972T (es)
NO (1) NO2550972T3 (es)
NZ (2) NZ597947A (es)
PE (1) PE20090227A1 (es)
PL (1) PL2550972T3 (es)
PT (1) PT2550972T (es)
RS (1) RS57149B1 (es)
SI (1) SI2550972T1 (es)
TW (3) TWI577387B (es)
WO (1) WO2009009173A2 (es)
ZA (1) ZA200906495B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009015050A2 (en) * 2007-07-20 2009-01-29 The Gov. Of The U.S.A. As Represented By The Secretary Of The Department Of Health & Human Services Gene expression profile for predicting ovarian cancer patient survival
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
EA032727B1 (ru) 2008-10-10 2019-07-31 Амген Инк. Мутантный резистентный к протеолизу полипептид fgf21 и его применение
CN102655877B (zh) * 2009-05-05 2017-04-05 安姆根有限公司 Fgf21突变体及其用途
JP2012525847A (ja) 2009-05-05 2012-10-25 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
EP2443145A1 (en) * 2009-06-17 2012-04-25 Amgen, Inc Chimeric fgf19 polypeptides and uses thereof
AU2010326024A1 (en) * 2009-12-02 2012-07-05 Amgen Inc. Binding proteins that bind to human FGFR1c, human beta-Klotho and both human FGFR1c and human beta-Klotho
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
JP2013523184A (ja) * 2010-04-15 2013-06-17 アムジエン・インコーポレーテツド ヒトＦＧＦ受容体およびβ−ＫＬＯＴＨＯ結合性タンパク質
AU2011239386B2 (en) 2010-04-16 2015-03-19 Salk Institute For Biological Studies Methods for treating metabolic disorders using FGF
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US20140189893A1 (en) * 2011-05-10 2014-07-03 Amgen Inc. Method of identifying compounds that specifically modulate the interaction of fgfr1 and beta klotho
HRP20191713T1 (hr) 2011-07-01 2019-12-27 Ngm Biopharmaceuticals, Inc. Pripravci, uporabe i metode za liječenje metaboličkih poremećaja i bolesti
US9475856B2 (en) 2012-03-02 2016-10-25 New York University Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders
US9464126B2 (en) 2012-06-07 2016-10-11 New York University Chimeric fibroblast growth factor 21 proteins and methods of use
US9474785B2 (en) 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
EP2925775B1 (en) 2012-11-28 2020-09-16 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
SG10202100667SA (en) 2012-12-27 2021-02-25 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US10090437B2 (en) 2013-02-11 2018-10-02 Lumileds Llc LED having etched light emitting surface for increased light extraction
WO2014130659A1 (en) 2013-02-22 2014-08-28 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
WO2015061331A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
US9925241B2 (en) 2013-10-21 2018-03-27 Salk Institute For Biological Studies Mutated fibroblast growth factor (FGF) 1 and methods of use
AP2016009156A0 (en) 2013-10-25 2016-04-30 Novartis Ag Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
US10369199B2 (en) 2013-10-28 2019-08-06 Ngm Biopharmaceuticals, Inc. Methods of using variants of FGF19 polypeptides for the treatment of cancer
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
PE20170256A1 (es) 2014-01-24 2017-04-22 Ngm Biopharmaceuticals Inc Proteinas de union y sus metodos de uso
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
PL3200786T3 (pl) 2014-10-03 2020-03-31 Novartis Ag Zastosowanie pochodnych pirydylowych o skondensowanym układzie bicyklicznym jako inhibitorów fgfr4
UA123763C2 (uk) 2014-10-23 2021-06-02 Енджіем Байофармасьютикалз, Інк. Фармацевтична композиція для контролю або лікування захворювання або порушення, пов’язаного з fgf19
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
WO2016151499A1 (en) 2015-03-25 2016-09-29 Novartis Ag Formylated n-heterocyclic derivatives as fgfr4 inhibitors
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
EP3368059A4 (en) 2015-10-30 2019-03-27 Salk Institute for Biological Studies TREATMENT OF STEROID-INDUCED HYPERGLYCEMIA WITH FIBROBLAST GROWTH FACTOR (FGF) -1 ANALOGUE
WO2017083276A1 (en) 2015-11-09 2017-05-18 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
CN107177002B (zh) * 2016-03-09 2021-02-09 郑州鸿运华宁生物医药有限公司 一种能与人β-Klotho受体特异性结合的抗体及其用途
CA3034399A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
WO2018055503A1 (en) 2016-09-20 2018-03-29 Novartis Ag Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
MA46712A (fr) 2016-11-02 2019-09-11 Novartis Ag Combinaisons d'inhibiteurs de fgfr4 et de chélateurs de l'acide biliaire
US20200330555A1 (en) * 2017-04-21 2020-10-22 Ngm Biopharmaceuticals, Inc. Methods of treating gastrointestinal motility-related disorders using variants and fusions of fgf19/fgf21 polypeptides
AU2018297285A1 (en) 2017-07-06 2020-01-30 Yale University Compositions and methods for treating or preventing endocrine FGF-linked diseases
CN109722480B (zh) * 2018-05-17 2022-04-26 上海交通大学 一种非小细胞肺癌检测试剂盒及其应用
CN109718385B (zh) * 2018-05-30 2022-05-10 上海交通大学 Klotho-beta的功能与应用
US11033146B2 (en) 2019-02-25 2021-06-15 Sharkninja Operating Llc Cooking device and components thereof
USD982375S1 (en) 2019-06-06 2023-04-04 Sharkninja Operating Llc Food preparation device
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose
CA3232472A1 (en) * 2021-09-23 2023-03-30 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-klb antibodies and uses
KR20250012564A (ko) 2022-05-19 2025-01-24 타이라 바이오사이언시스, 인크. Ppar 효현제 및 fgfr4 저해제를 이용한 치료법
EP4509142A1 (en) 2023-08-16 2025-02-19 Ona Therapeutics S.L. Fgfr4 as target in cancer treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020042367A1 (en) 1997-11-25 2002-04-11 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
JP2001072607A (ja) * 1999-09-03 2001-03-21 Kyowa Hakko Kogyo Co Ltd 新規血管内皮機能改善法
WO2001020031A2 (en) 1999-09-10 2001-03-22 Kyowa Hakko Kogyo Co Ltd Polymorphisms in a klotho gene
JP2003334088A (ja) * 2002-05-22 2003-11-25 Pharma Design Inc ヒト由来の新規Ｋｌｏｔｈｏ様タンパク質及びその遺伝子
JP2006158339A (ja) * 2004-12-09 2006-06-22 Kyoto Univ βＫｌｏｔｈｏ遺伝子、Ｃｙｐ７ａ１遺伝子、及びそれらの利用
US7678373B2 (en) * 2006-02-10 2010-03-16 Genentech, Inc. Anti-FGF19 antibodies and methods using same

Also Published As

Publication number Publication date
US20150132309A1 (en) 2015-05-14
LT2550972T (lt) 2018-05-10
ES2422605T3 (es) 2013-09-12
WO2009009173A2 (en) 2009-01-15
US20210284753A1 (en) 2021-09-16
AU2008275559B2 (en) 2014-04-10
EP2139508B1 (en) 2013-05-08
NZ597947A (en) 2013-08-30
AU2008275559A1 (en) 2009-01-15
TW200906438A (en) 2009-02-16
US20220089780A1 (en) 2022-03-24
EP2550972B1 (en) 2018-02-21
HUE038279T2 (hu) 2018-10-29
PL2550972T3 (pl) 2018-08-31
PT2550972T (pt) 2018-05-02
PE20090227A1 (es) 2009-04-03
CL2008000947A1 (es) 2008-10-10
EP2550972A1 (en) 2013-01-30
TWI524898B (zh) 2016-03-11
EP3372237A1 (en) 2018-09-12
US20100158914A1 (en) 2010-06-24
SI2550972T1 (en) 2018-05-31
ZA200906495B (en) 2010-11-24
NO2550972T3 (es) 2018-07-21
US20150368358A1 (en) 2015-12-24
TWI577387B (zh) 2017-04-11
NZ580180A (en) 2012-03-30
CA2682096A1 (en) 2009-01-15
ES2665996T3 (es) 2018-04-30
HRP20180667T1 (hr) 2018-06-01
US20180208677A1 (en) 2018-07-26
WO2009009173A3 (en) 2009-10-29
US20140363435A1 (en) 2014-12-11
DK2550972T3 (en) 2018-04-23
TW201412331A (zh) 2014-04-01
TW201446265A (zh) 2014-12-16
RS57149B1 (sr) 2018-07-31
CL2017002807A1 (es) 2018-05-11
EP2139508A2 (en) 2010-01-06

Similar Documents

Publication Publication Date Title
AR065911A1 (es) Beta - klotho
Brand et al. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
Kim et al. Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer
Scheuer et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models
JP6449308B2 (ja) がんバイオマーカー及びその使用
Xu et al. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity
Kim Targeted therapies for the treatment of cancer
Leconet et al. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy
Lee et al. Papillary thyroid cancer–derived exosomes contain miRNA-146b and miRNA-222
Hui et al. Significance of dysregulated metadherin and microRNA-375 in head and neck cancer
EP3834843A1 (en) Combination of antibody-drug conjugate and tubulin inhibitor
RU2587619C2 (ru) Антагонисты неурегулина и применение их в лечении злокачественного новообразования
Ebbing et al. Esophageal adenocarcinoma cells and xenograft tumors exposed to Erb-b2 receptor tyrosine kinase 2 and 3 inhibitors activate transforming growth factor beta signaling, which induces epithelial to mesenchymal transition
US10640556B2 (en) Anti amphiregulin antibodies, compositions comprising same and uses thereof
Scartozzi et al. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan–cetuximab
Leblanc et al. Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
MY150756A (en) Tumor theraphy with an anti-vegf antibody
Xu et al. Hsa_circ_0001869 promotes NSCLC progression via sponging miR-638 and enhancing FOSL2 expression
CA2862739A1 (en) Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
Chia et al. Epidermal growth factor receptor (EGFR)-targeted therapies in mesothelioma
JP2014526891A (ja) ニューレグリン抗体とその使用
Elliott et al. Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification
US12312641B2 (en) Sensitivity marker for antibody-drug conjugate
E Griner et al. Mechanisms of adipocytokine-mediated trastuzumab resistance in HER2-positive breast cancer cell lines
Nelhűbel et al. EGFR alterations influence the cetuximab treatment response and c-MET tyrosine-kinase inhibitor sensitivity in experimental head and neck squamous cell carcinomas

Legal Events

Date Code Title Description
FB Suspension of granting procedure